公开(公告)号：US11806374B2

公开(公告)日：2023-11-07

申请号：US16650863

申请日：2018-07-03

Applicant: HANGZHOU CONVERD CO., LTD.

Inventor： Jipo Sheng ,  Jin Fu ,  Ronghua Zhao ,  Yun Qin ,  Lin Chen ,  Sanmao Kang ,  Fang Hu

IPC: A61K39/23 ,  C12N15/79 ,  C07H21/04 ,  A61K35/761 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N15/63 ,  A61K48/00 ,  C12N15/64

CPC classification number: A61K35/761 ,  A61K48/005 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/63 ,  C12N15/64 ,  C12N2310/531 ,  C12N2710/10332 ,  C12N2710/10343

Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

公开(公告)号：US20200289591A1

公开(公告)日：2020-09-17

申请号：US16650076

申请日：2018-06-28

Applicant: Hangzhou Converd Co., Ltd.

Inventor： Jin Fu ,  Ronghua Zhao ,  Rong Zhang ,  Tingting Wang ,  Lin Chen ,  Fang Hu

IPC: A61K35/768 ,  C12N7/00 ,  A61P35/00

Abstract: The invention provides an isolated recombinant oncolytic vaccinia virus, pharmaceutical compositions and uses thereof for drugs for treatment of tumors and/or cancers. The isolated recombinant oncolytic vaccinia virus is functionally deficient in the TK gene and the VGF gene, and the genome of the recombinant oncolytic vaccinia virus is integrated with an exogenous IL-21 gene, and wherein the IL-21 gene is capable of being expressed in tumor cells. The recombinant oncolytic vaccinia virus can selectively replicate in tumor cells, and can also fully exert the anti-tumor immune effect of the exogenous IL-21, such that the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation effect of IL-21 achieve a synergic effect.